BIO vs EXPE · rev $651.0M vs P/E 20, rev $7.74B
BIO (BIO) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
BIO currently screens at market cap $0. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the BIO and EXPE stock pages for the full models.
Not investment advice.